Please login to the form below

Not currently logged in
Email:
Password:

Sepracor signs EU marketing deal with GSK

Sepracor signs an agreement to market its sleep drug Lunivia with GSK in the EU

US-headquartered drug development company Sepracor has signed an agreement to market its sleep drug Lunivia (eszopiclone) in the EU with UK-based pharmaceutical company, GlaxoSmithKline (GSK).

Lunivia is currently under market review in the region, but has been commercially available in the US as Lunesta since 2005 to treat insomnia. Per the agreement, the drug will be marketed by GSK everywhere, except the US, Canada, Japan and Mexico.

Sepracor will receive an initial payment of USD 20m from GSK and is entitled to USD 155m in license and milestone payments, as well as double-digit royalties which would escalate upon increased product sales, says the firm.

In FY06, US product sales were about USD 566.8m, while the EU sedative hypnotic market was estimated to be worth about USD 500m in 2006.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics